Alkermes (ALKS) Change in Accured Expenses (2010 - 2026)
Alkermes (ALKS) reported Change in Accured Expenses of $4.9 million for Q1 2026, up 71.48% year-over-year from $2.9 million in Q1 2025, and up 121.66% quarter-over-quarter from -$22.6 million in Q4 2025.
Alkermes (ALKS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Change in Accured Expenses data on file, last reported at $4.9 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $4.9 million, up 71.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (down 35.61% YoY), and the FY2025 annual result was $5.3 million, down 37.21% from the prior year.
- Change in Accured Expenses climbed to $4.9 million in Q1 2026 per ALKS's latest filing, from -$22.6 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $91.4 million in Q4 2024 and troughed at -$84.0 million in Q3 2024.
- A 5-year average of $3.4 million and a median of $2.9 million in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses tumbled 15298.16% in 2022, then jumped 4356.75% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $9.1 million in 2022, then sank by 77.58% to $2.1 million in 2023, then jumped by 4356.75% to $91.4 million in 2024, then tumbled by 124.69% to -$22.6 million in 2025, then jumped by 121.66% to $4.9 million in 2026.
- Business Quant data shows ALKS's Change in Accured Expenses at $4.9 million in Q1 2026, -$22.6 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 23.00 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 10.02 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 14.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.89 Mn |
| Mar 31, 2026 | 4.89 Mn |
| Dec 31, 2025 | -22.57 Mn |
| Dec 31, 2025 | -22.57 Mn |
| Sep 30, 2025 | 27.82 Mn |
| Sep 30, 2025 | 27.82 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Jun 30, 2025 | -2.80 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 91.41 Mn |
| Dec 31, 2024 | 91.41 Mn |
| Sep 30, 2024 | -83.99 Mn |
| Sep 30, 2024 | -83.99 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | -105,000.00 |
| Mar 31, 2024 | -105,000.00 |
| Dec 31, 2023 | 2.05 Mn |
| Dec 31, 2023 | 2.05 Mn |